Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00083509" target="_blank" >RIV/00216224:14110/15:00083509 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/15:00063156
Result on the web
<a href="http://dx.doi.org/10.1161/JAHA.114.001505" target="_blank" >http://dx.doi.org/10.1161/JAHA.114.001505</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1161/JAHA.114.001505" target="_blank" >10.1161/JAHA.114.001505</a>
Alternative languages
Result language
angličtina
Original language name
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Original language description
Background-Vorapaxar is a protease-activated receptor-1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) and peripheralartery disease (PAD), without a previous stroke or transient ischemic attack (TIA). Methods and Results-We examined the efficacy and safety of vorapaxar in the intended use population, considering 20 170 patients randomized in the multinational, double-blinded, placebo-controlled TRA 20P-TIMI 50 trial. Of these, 16 897 qualified with a history of MI in the prior 2 weeks to 1 year and 3273 with PAD. At baseline 97% of the patients were treated with aspirin, 71% with a thienopyridine, and 93% a statin. At3 years, the endpoint of CV death, MI, or stroke was significantly reduced with vorapaxar compared with placebo (7.9% versus 9.5%, HR, 0.80; 95% CI 0.73 to 0.89; P<0.001).
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of the American Heart Association
ISSN
2047-9980
e-ISSN
—
Volume of the periodical
4
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
"e001505"
UT code for WoS article
000351520300011
EID of the result in the Scopus database
—